Piper Sandler downgraded Q32 Bio (QTTB) to Neutral from Overweight with a price target of $4, down from $20. The firm is surprised by the company’s decision to discontinue complement inhibitor ...

Q32 Bio (NASDAQ:QTTB – Get Free Report) is expected to be releasing its earnings data before the market opens on Tuesday, March 11th.Analysts expect Q32 Bio to post earnings of ($1.25) per share ...

WALTHAM, Mass., Feb. 4, 2025 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune ...

QTTB stock opened at $2.88 on Tuesday. Q32 Bio has a 12-month low of $2.60 and a 12-month high of $53.79. The company has a quick ratio of 6.53, a current ratio of 6.53 and a debt-to-equity ratio ...